Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 250Lung Neoplasms 176Small Cell Lung Carcinoma 37Breast Neoplasms 37Neoplasms 25Neoplasm Metastasis 19Adenocarcinoma of Lung 17Ovarian Neoplasms 14Mesothelioma, Malignant 14Melanoma 13Stomach Neoplasms 12Mesothelioma 12Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Prostatic Neoplasms 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Renal Cell 9Lung Diseases 7Head and Neck Neoplasms 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Sarcoma 5Pleural Effusion, Malignant 5Carcinoma, Ovarian Epithelial 5Carcinoma 5

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Locally Advanced Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡